^
    2d
    MEDOPP824: Phase II study to improve sacituzumab govitecan tolerance with atropine in patients with advanced triple-negative and hormone receptor-positive/HER2-negative breast cancer (The SATROPIN Study). (2025-524109-33-00)
    P1/2, N=30, Not yet recruiting, Medica Scientia Innovation Research S.L.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim)
    9d
    Efficacy of the Granulocyte Colony-Stimulating Factor in Sepsis-Associated Immunosuppression: An Open-Label Randomized Controlled Trial. (PubMed, Cureus)
    Filgrastim (G-CSF) use in immunocompetent children with sepsis-induced MOFS is safe, and a 2-dose of filgrastim (G-CSF) for three days has poor efficacy in the reduction of mortality and did not show significant change in frequency of HAI, TNF-α levels, and pSOFA scores.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • FASLG (Fas ligand) • FAS (Fas cell surface death receptor)
    |
    Neupogen (filgrastim)
    10d
    Poly-Infections in a Patient Living With Human Immunodeficiency Virus (HIV). (PubMed, Cureus)
    Bone marrow examination combined with genetic and molecular testing revealed a diagnosis of T-cell large granular lymphocytic leukemia (T-LGL), which explained the lack of response to tbo-filgrastim...Undiagnosed T-LGL may present with gram-negative bacteremia and failure to respond to granulocyte colony-stimulating factor (G-CSF), and Strongyloides infection should be considered in immunocompromised patients who are being evaluated for occult malignancy, even without identifiable epidemiological risk factors. Early recognition of these conditions can guide timely evaluation and appropriate therapy in complex immunocompromised hosts.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Neupogen (filgrastim)
    15d
    Febrile neutropenia caused by the rare organism Phytobacter: first Case Report from India. (PubMed, Front Med (Lausanne))
    A 62-year-old woman with HER2-positive, cT4bN2M0 breast cancer receiving neoadjuvant trastuzumab, carboplatin, and docetaxel presented with fever, headache, profound fatigue, pallor, and retinal hemorrhages...The patient was managed with blood component transfusions, filgrastim, and empirical piperacillin-tazobactam...Gram-negative infections caused by phytobacteria are likely underreported with the automated VITEK-2 identification system. This first molecularly confirmed case of Phytobacter diazotrophicus identified by 16S rDNA sequencing in India underscores the need for heightened clinical awareness, prompt and accurate microbiological identification, and vigilance regarding antimicrobial resistance, especially in the immunocompromised population.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Neupogen (filgrastim)
    24d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2034 --> Dec 2035 | Trial primary completion date: Dec 2030 --> Dec 2031
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    30d
    HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, St. Jude Children's Research Hospital | N=140 --> 69 | Trial completion date: Aug 2025 --> Jun 2026
    Enrollment change • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • DEK (DEK Proto-Oncogene) • AFDN (Afadin, Adherens Junction Formation Factor) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    FLT3-ITD mutation
    |
    cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    30d
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=97, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane) • MPO (Myeloperoxidase)
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    1m
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov)
    P2, N=60, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jan 2028 --> Mar 2029 | Trial primary completion date: Feb 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim)
    1m
    PRESERVE I: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Ossium Health, Inc. | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    1m
    Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov)
    P2, N=41, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • paclitaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • melphalan • mesna • Neupogen (filgrastim)
    1m
    Stem Cell Transplantation in Crohn's Disease (clinicaltrials.gov)
    P1/2, N=15, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • mesna • Neupogen (filgrastim) • methylprednisolone sodium succinate
    1m
    Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P2, N=33, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ABL1 (ABL proto-oncogene 1) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive • CD20 negative
    |
    Rituxan (rituximab) • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)